Denali Therapeutics Inc (DNLI.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|Chairman of the Board, Co-Founder|
|2016||President, Chief Executive Officer, Co-Founder, Director|
|Co-Founder, Chief Operating Officer, Head of Corporate Development|
|48||Chief Financial Officer|
|Chief Medical Officer|
- BRIEF-Temasek Holdings Dissolves Share Stake In Marin Software, Takes Share Stake In Denali Therapeutics
- BRIEF-Denali Therapeutics, Lonza Pharma & Biotech Announce Exclusive Partnership To Develop And Produce Biologic Medicines
- BRIEF-Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases
- BRIEF-Denali Therapeutics Says Initial Public Offering Of 13.9 Mln Common Shares Priced At $18 per Share
- BRIEF-Denali Therapeutics Now Sees IPO Of 13.9 Million Shares Priced Between $17-$19 Per Share